Genetic Clues for Skin Cancer Therapies Rochester NY

Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.

Local Companies

Marc D Brown
(585) 275-9208
601 Elmwood Ave
Rochester, NY
WALTER MARKOWITCH, MD
(585) 922-4121
1425 Portland Avenue
Rochester, NY
WALTER BROOKS, MD
(585) 719-9600
730 Weiland Road
Rochester, NY
Patrick James Condry, MD
585-719-9600
730 Weiland Rd
Rochester, NY
Allison Leslie Holm, MD
585-271-2070
30 N Union St
Rochester, NY
Walter S Brooks
(585) 719-9600
730 Weiland Rd
Rochester, NY
JAMES SEAB, MD
(585) 586-5166
61 Monroe Avenue
Pittsford, NY
ELAINE GILMORE, MD
(585) 275-2705
601 Elmwood Avenue
Rochester, NY
BRETT SHULMAN, MD
(585) 922-9770
1850 Brighton Henrietta Town Line Road
Rochester, NY
Richard Myron Greene, MD
585-256-0555
2150 Clinton Ave S
Rochester, NY
Data Provided by:
    

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations.

Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma. Their study is published in the September issue of the journal Nature Genetics.

"We have found what appears to be an Achilles' heel of a sizable share of melanomas," Samuels, an investigator in the cancer genetics branch of the institute's Division of Intramural Research, said in a NIH news release.

The PTK family includes many genes that, when mutated, promote many types of cancer, including brain, gastric and lung malignancies, according to background information provided in the news release. In the new NIH study, one PTK gene that appeared particularly suspicious was the ERBB4 gene. Scientists found ERBB4 mutations in 19 percent of patients' tumors, making it the most frequently mutated PTK gene in melanoma. Additional lab studies found that melanoma cells with the ERBB4 defect were dependent on the mutant gene for their growth.

The researchers also found that two additional PTK genes -- FLT1 and PTK2B -- were mutated in about 10 percent of the tumor samples.

The discoveries could open up new avenues for therapies. For example, the researchers discovered that melanoma cells grew much more slowly when exposed to lapatinib (Tykerb), a chemotherapy drug that inhibits ERBB4. Lapatinib is already in use by some breast cancer patients. The NIH team is planning a clinical trial using lapatinib in patients with metastatic melanoma harboring ERBB4 mutations.

"Though additional work is needed to gain a more complete understanding of these genetic mutations and their roles in cancer biology, our findings open the door to pursuing specific therapies that may prove useful for the treatment of melanoma with ERBB4 mutations," Samuels stated.

More information

The American Cancer Society has more on melanoma.

SOURCE: U.S. National Institutes of Health, news release, Aug. 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Risks for Childhood Cancer Survivors Rochester NY
People who survived cancer as children face a high lifelong risk for developing another cancer, a new study has found. A study that appears online May 26 in the Journal of the National Cancer Institute went further than earlier studies by following people from birth through age 79. The researchers analyzed data on more than 47,000 people who had been diagnosed with cancer before the age of 20.
- High Levels of Selenium Decreases Incidence of Skin Cancer. Rochester NY
- Gene Mutation in Dogs Rochester NY
- Getting a Botox Cosmetic Injection Rochester NY
- Follow Up After Skin Cancer Rochester NY
- Delayed Prostate Cancer Therapy Rochester NY
- Risk Factors for Squamous Cell Cancer of the Skin Rochester NY
- Breast Cancer Treatment Rochester NY
- Healing Facial Spider Veins Rochester NY
- Filling in Wrinkles with Dermal Fillers Rochester NY